Azathioprine (AZA), 6-mercaptopurine (6-MP), and thioguanine (TG) are thiopurine drugs. These agents are indicated for the treatment of various diseases including hematologic malignancies, inflammatory bowel disease (IBD), rheumatoid arthritis, and as immunosuppressants in solid organ transplants. Thiopurine drugs are metabolized, in part, by thiopurine methyltransferase (TPMT). TPMT displays genetic polymorphism resulting in null or decreased enzyme activity. At least 20 polymorphisms have been identified, of which, TPMT *2, *3A, *3B, *3C, and *4 are the most commonly studied. These polymorphisms have been associated with increased myelosuppression risk. TPMT genotyping may be useful to predict this risk.

Based on a WTP defined at $50,000 per QALY gained, bevacizumab was cost-effective versus ranibizumab 95% of the time because of lower acquisition costs and increased efficacy.

Etanercept+MTX was a cost-effective treatment strategy in the base-case scenario; however, the model was sensitive to parameter uncertainties and ACR response criteria. Although Bayesian methods were used to determine transition probabilities, future studies will need to focus on head-to-head comparisons of multiple TNF-α inhibitors to provide valid comparisons.

No abstract

The authors have reported a number of corrections to their analysis following the Letter to the Editor by Diamantopoulos et al. [1] These corrections have not affected the conclusions of the article but have resulted in a number of changes to the cost and utility results presented throughout the text, figures and tables. In addition, a wider range of utility values were tested in the one-way sensitivity analyses as the corrections resulted in a wider variance than previously reported. Please refer to Bounthavong et al.'s reply [2] to Diamantopoulos et al. for a more comprehensive explanation of these errors and to the online corrected version for correct cost and utility results.